The peptide BPC 157 completely reversed gastrointestinal, liver, and brain damage caused by major bowel surgery and diclofenac toxicity in rats, even when nitric oxide signaling was blocked.
Complete amelioration across all conditionsBPC 157 fully reversed gastrointestinal, liver, and brain lesions caused by bowel surgery, diclofenac, and nitric oxide blockade — even at the nanogram dose level
What the researchers found
BPC 157 completely ameliorated symptoms in short-bowel rats across all experimental conditions: surgery alone, surgery plus diclofenac, and surgery plus diclofenac plus the NOS blocker L-NAME. This included protection of anastomosis healing, restoration of intestinal adaptation, and reduction of gastrointestinal, liver, and brain lesions.
The damage cascade was dose-dependent: surgery alone caused mild stomach/duodenum lesions with severe brain lesions; adding diclofenac (12 mg/kg) caused widespread severe lesions across all organs; adding L-NAME on top made everything worse with macro/microscopic necrosis. BPC 157 at both 10 μg/kg and 10 ng/kg reversed all of these. L-arginine only helped reverse L-NAME-specific aggravation.
Why it matters
Major bowel surgery carries significant risks of complications including anastomosis failure, organ damage, and impaired intestinal adaptation. NSAIDs like diclofenac, commonly used for post-surgical pain, can worsen these outcomes. BPC 157’s ability to protect multiple organ systems simultaneously — gut, liver, and brain — through what appears to involve the COX-NO system suggests it could be a valuable therapeutic agent for post-surgical recovery, particularly in situations where NSAID use is necessary.
How the study worked
Wistar rats underwent massive small bowel resection with anastomosis creation. Immediately after surgery, rats were given intraperitoneal injections of diclofenac (12 mg/kg), BPC 157 (10 μg/kg or 10 ng/kg), L-NAME (5 mg/kg), L-arginine (100 mg/kg), alone or in combinations. Animals were assessed 24 hours later for anastomosis healing quality, intestinal adaptation, and macro/microscopic lesions in the gastrointestinal tract, liver, and brain (cerebrum, hippocampus, cerebellum).
What this study cannot tell us
This is an animal study with only a 24-hour follow-up period, which cannot predict long-term outcomes or human responses. The sample size per group is not specified in the abstract. The research comes from a single lab group (Sikiric et al.) that produces the majority of BPC 157 research, limiting independent replication. The mechanisms by which BPC 157 achieves such broad protective effects remain incompletely understood. No human surgical studies with BPC 157 exist.
How to read the evidence
This is a preclinical animal study in rats with a short 24-hour follow-up. While it demonstrates strong effects, the results are limited by the animal model, single research group, and lack of human data. The broad claims of complete amelioration across multiple organ systems require independent replication.
When this study was published
Published in 2016, this study is moderately dated but remains relevant as BPC 157 research continues to expand. The findings are consistent with the broader BPC 157 literature and have informed subsequent studies on the peptide’s mechanisms.
The bigger picture
This study is part of an extensive body of BPC 157 research from the Sikiric lab group, which has published numerous studies on this gastric pentadecapeptide’s wound-healing and protective properties. The finding that BPC 157 works across multiple organ systems and overcomes COX-NO system inhibition adds to the evidence for its broad cytoprotective mechanism. However, BPC 157 research remains predominantly preclinical, and human clinical trials are still limited.
Questions still open
- Through what specific molecular mechanisms does BPC 157 provide simultaneous protection to the gut, liver, and brain after surgical trauma?
- Would BPC 157’s protective effects persist beyond the 24-hour window and improve long-term surgical outcomes?
- Can these dramatic preclinical results be translated to human post-surgical care, and if so, what would be the optimal dosing and timing?
Common questions
What is BPC 157?
Why did the researchers test BPC 157 together with diclofenac?
Read the original research
Effects of Diclofenac, L-NAME, L-Arginine, and Pentadecapeptide BPC 157 on Gastrointestinal, Liver, and Brain Lesions, Failed Anastomosis, and Intestinal Adaptation Deterioration in 24 Hour-Short-Bowel Rats.
PloS one, 11(9), e0162590
Citation
Lojo, Nermin; Rasic, Zarko; Zenko Sever, Anita; Kolenc, Danijela; Vukusic, Darko; Drmic, Domagoj; Zoricic, Ivan; Sever, Marko; Seiwerth, Sven; Sikiric, Predrag. (2016). Effects of Diclofenac, L-NAME, L-Arginine, and Pentadecapeptide BPC 157 on Gastrointestinal, Liver, and Brain Lesions, Failed Anastomosis, and Intestinal Adaptation Deterioration in 24 Hour-Short-Bowel Rats.. PloS one, 11(9), e0162590. https://doi.org/10.1371/journal.pone.0162590